Intuitive Surgical Inc Overview
Industry: Medical Instruments & Supplies
Sector: Healthcare
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California. Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery us Read MoreIntuitive Surgical Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
Intuitive Surgical Inc
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $2.8B (+23% YoY); EPS was $ (reported).
What changed
- Revenue +23% YoY to $2.8B; EPS reported to $.
- Net income +3% YoY to $826M.
Guidance / outlook
The Company expects the following results for the full year of 2026: • Worldwide da Vinci procedure growth of approximately 13.5% to 15.5% in 2026. • Non-GAAP* gross profit margin to be within a range of 67.5% and 68.5% of revenue in 2026. This range includes an estimated impact from tariffs of 1.0% of revenue.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Recent News
Earnings Per Share
Return on Equity
ROE
Company 0%
Sector Median 0%
ROE
Company 0%
Sector Median 0%
ROE
Company 0%
Sector Median 0%
ROE
Company 0%
Sector Median 0%
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company 0%
Sector Median 0%
Net Margin
Company 0%
Sector Median 0%
Net Margin
Company 0%
Sector Median 0%
Net Margin
Company 0%
Sector Median 0%
Metric chart temporarily unavailable.
Leverage
Leverage
Company 0
Sector Median 0
Leverage
Company 0
Sector Median 0
Leverage
Company 0
Sector Median 0
Leverage
Company 0
Sector Median 0
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.